💊 Arzneimittel A-Z 🧬 Targets 🛠 Werkzeuge 📚 Leitfäden
Alle Arzneimittel Arzneimittelklassen Therapeutische Bereiche Nebenwirkungen
Leitfäden Glossar Zeitleiste
Vergleiche Arzneimittelreisen Arzneimittel-Wirkstoffgruppen
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Radium Dichloride

CHEMBL2111187 Phase 4 Zugelassen Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Radium dichloride (radium-223 dichloride, Xofigo) is a targeted alpha-emitting radiopharmaceutical that, as a calcium mimetic, selectively incorporates into areas of increased bone turnover (osteoblastic metastases), delivering high-linear-energy-transfer alpha radiation to metastatic foci while minimizing systemic exposure. It is approved for the treatment of castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastatic disease.

Therapeutische Bereiche

Thyroid Cancer Pain Management Breast Cancer Chronic Pain Prostate Cancer

Wirkmechanismus

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

2D-Struktur

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cl[Ra]Cl

                

                

                
                

                    
InChI

                    
InChI=1S/2ClH.Ra/h2*1H;/q;;+2/p-2

                

                

                

                    
                    

                        
HBD / HBA

                        
- / -

                    

                    
                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Häufig gestellte Fragen

                

                    
                    

                        
                        

                            
Radium dichloride (radium-223 dichloride, Xofigo) is a targeted alpha-emitting radiopharmaceutical that, as a calcium mimetic, selectively incorporates into areas of increased bone turnover (osteoblastic metastases), delivering high-linear-energy-transfer alpha radiation to metastatic foci while minimizing systemic exposure. It is approved for the treatment of castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastatic disease.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Radium Dichloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2111187.
                Open-access bioactivity database.
            
        
    • 
        
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.




        


        
        
    


    



    
Medizinischer Haftungsausschluss

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.